Is Gilead Sciences, Inc. (NASDAQ: GILD) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

GILD belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – General industry. The current market capitalization of Gilead Sciences, Inc. is $84.42B. A total of 5.36 million shares were traded on the day, compared to an average of 7.66M shares.

In the most recent transaction, Parsey Merdad sold 2,000 shares of GILD for 68.63 per share on Jul 01 ’24. After the transaction, the Chief Medical Officer now owns 96,380 company shares. In a previous transaction on Apr 02 ’24, GILEAD SCIENCES, INC. bought 485,250 shares at 0.76 per share. GILD shares that 10% Owner owns now total 7,345,473.

Among the insiders who sold shares, Parsey Merdad disposed of 2,000 shares on Apr 01 ’24 at a per-share price of $72.96. This resulted in the Chief Medical Officer holding 96,304 shares of GILD after the transaction. In another insider transaction, Parsey Merdad sold 8,230 shares at $72.74 per share on Feb 29 ’24. Company shares held by the Chief Medical Officer now total 92,706.

Dividend

Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Gilead Sciences, Inc. pays an annual dividend of $3.04, resulting in a dividend yield of 4.49%, and it has a price to earnings (P/E) ratio of 188.90. GILD’s most recent ex-dividend date was 6/14/2024 when it declared a $0.77 quarterly dividend that was paid in cash on 6/27/2024. Previously, the company paid the dividend on 3/28/2024 with an ex-dividend date of 3/14/2024. The GILD stock dividend was $0.77 per share in cash.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, GILD has a high of $87.86 and a low of $62.07.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $14.08, while its Total Shareholder’s Equity was $21.06B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 3.92.

Most Popular

Related Posts